Answers are grounded in this paper and cite their sources.
AMD is the leading cause of blindness and is found in elderly patients. Lutein is a carotenoid and has antioxidant properties hence acting as a neuroprotective in the macular region. However, for the treatment of AMD, prolonged therapy is required from several months to years. This study was intended to design and characterize the long-acting thin-film nanofibers of lutein for the treatment of AMD. The thin-film was fabricated by electrospinning followed by the sintering technique. The fabricated lutein-loaded thin-film was characterized for entrapment efficiency, in-vitro drug release, in-vivo injection feasibility, antioxidant property and morphological studies. LP-nanofibers shown sustained release of encapsulated lutein 81.75% in 2 months. This indicate that fabricated LP-nanofibers sustain the drug for long period in the posterior segment of the eye and it will be an effective therapy for the treatment of AMD.
No takes yet. Share an insight, caveat, or question.
Garkal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: